Project Grant R44AI197364
Award Date 8/1/26
Completion Date 1/31/27
Dollars Obligated $299K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University $909,998 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize antibody-mediated establishment of an SIV reservoir using an art-free approach. The project, designated R01AI198034, runs through January 31, 2031, with place of performance in Atlanta, Georgia. The research employs adeno-associated virus (AAV) vectors to deliver broadly neutralizing...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $889,519 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop multi-biologic, adeno-associated virus (AAV)-deliverable HIV-1 therapeutics for potential functional cure applications. The funded research advances AAV-vector delivery of broadly neutralizing antibodies and ECD4-IG, a potency and half-life...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded San Diego Biomedical Research Institute $809,479 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered native HIV envelope glycoprotein trimers that induce broadly neutralizing antibodies (BNAbs) targeting the CD4-binding site. The research addresses two critical limitations in current HIV-1 vaccine strategies. First, existing boosting immunogens lack the stringency...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $894,998 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate intrinsic CD4 T cell barriers to HIV-1 latency reversal. The research addresses HIV-1 persistence in CD4 T cells despite effective antiretroviral therapy by examining post-transcriptional mechanisms that constrain productive viral gene expression. The investigator will integrate...
- The National Institute of Allergy and Infectious Diseases awarded $1.744 million to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support the MAATCH project—Modeling Antibody Approaches for a Tailored Cure for HIV. The award funds laboratory-based experiments and mathematical modeling to determine the degree of personalization required to advance antibody-based HIV...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $251,875 on May 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to explore the structural basis of antibody-mediated Fc-effector functions in HIV-1 immune complexes. The research establishes a cryo-electron microscopy platform to directly observe how antibodies bound to HIV-1 envelope glycoproteins on virions are recognized by Fc gamma receptors on plasma membrane blebs and...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $149,190 on December 25, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel antiviral compounds targeting lenacapavir-resistant HIV. The research will characterize three novel capsid effectors designed to overcome resistance-associated mutations in HIV that render lenacapavir ineffective. The work comprises three aims: biochemical and biophysical assessment of each...
- The National Institute of Allergy and Infectious Diseases awarded San Diego Biomedical Research Institute $992,920 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on nanoscale imaging of cell surface HIV envelope immune complexes to optimize natural killer cell antibody-dependent cellular cytotoxicity (ADCC) therapeutics. The project integrates nanoscale imaging, machine learning, and in silico protein modeling to characterize the...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $794,984 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support structure-based discovery and development of next-generation soluble CD4 (sCD4) immunotherapeutics for HIV treatment. The funded research targets HIV's obligate dependence on CD4 for viral entry by engineering a new class of potent, broad, and long-acting sCD4-D1-based bifunctional...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology (MIT) $553,136 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research visualizing HIV-1 capsid passage through the nuclear pore complex. The funded work addresses how HIV-1 traverses the nuclear pore complex during viral entry into the cell nucleus, a critical stage in the infection process preceding uncoating, reverse transcription, and...